CDXS Logo 2 April 2021.jpg
Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance
July 14, 2022 16:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced preliminary...
CDXS Logo 2 April 2021.jpg
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
June 17, 2022 08:00 ET | Codexis, Inc.
Collaboration with Merck published in Science magazine REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the...
CDXS Logo 2 April 2021.jpg
Codexis to Participate in Upcoming Healthcare Conferences
May 25, 2022 16:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that...
CDXS Logo 2 April 2021.jpg
Codexis to Participate in Upcoming Healthcare Conferences
May 17, 2022 16:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
CDXS Logo 2 April 2021.jpg
Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
May 16, 2022 08:00 ET | Codexis, Inc.
REDWOOD CITY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that three of its...
CDXS Logo 2 April 2021.jpg
Codexis Reports First Quarter 2022 Financial Results
May 05, 2022 16:05 ET | Codexis, Inc.
Total Revenue up 96% and Product Revenue up 200% YOY; Product Gross Margin Expands to 72% Reiterating Guidance for 2022, Including Total Revenue of $152 - $158M REDWOOD CITY Calif., May 05, 2022 ...
CDXS Logo 2 April 2021.jpg
Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
May 02, 2022 16:35 ET | Codexis, Inc.
REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster...
CDXS Logo 2 April 2021.jpg
Codexis to Report First Quarter 2022 Financial Results on May 5
April 21, 2022 16:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
CDXS Logo 2 April 2021.jpg
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
April 21, 2022 08:00 ET | Codexis, Inc.
seqWell raises $7M Series C funding, led by CodexisCurrent investors Research Corporation Technologies and BroadOak Capital Partners also participated in the roundNew funding will be used to...
CDXS Logo 2 April 2021.jpg
Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
April 12, 2022 08:00 ET | Codexis, Inc.
Molecular Assemblies has pioneered Fully Enzymatic Synthesis™ (or FES™) technology with an in-process purification step to overcome the length, purity, and accuracy limitations of the current chemical...